Atrion (NASDAQ:ATRI) Now Covered by StockNews.com

Research analysts at StockNews.com began coverage on shares of Atrion (NASDAQ:ATRI) in a report issued on Monday. The firm set a “sell” rating on the medical instruments supplier’s stock.

Atrion Trading Up 0.3 %

NASDAQ:ATRI opened at $453.39 on Monday. Atrion has a 1-year low of $274.98 and a 1-year high of $593.00. The business’s 50-day moving average price is $447.85 and its two-hundred day moving average price is $404.39. The firm has a market capitalization of $797.97 million, a price-to-earnings ratio of 42.61 and a beta of 0.68.

Atrion (NASDAQ:ATRI) last announced its quarterly earnings data on Friday, May 10th. The medical instruments supplier reported $1.59 EPS for the quarter. Atrion had a net margin of 10.60% and a return on equity of 7.75%. The company had revenue of $47.33 million during the quarter.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the stock. Vanguard Group Inc. raised its holdings in shares of Atrion by 0.4% during the first quarter. Vanguard Group Inc. now owns 84,876 shares of the medical instruments supplier’s stock valued at $39,344,000 after purchasing an additional 326 shares during the period. Boston Trust Walden Corp grew its position in Atrion by 4.8% during the fourth quarter. Boston Trust Walden Corp now owns 35,091 shares of the medical instruments supplier’s stock valued at $13,292,000 after buying an additional 1,609 shares during the period. Charles Schwab Investment Management Inc. grew its position in shares of Atrion by 2.4% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 10,385 shares of the medical instruments supplier’s stock valued at $4,291,000 after acquiring an additional 243 shares during the period. Penn Mutual Asset Management LLC purchased a new stake in Atrion in the fourth quarter worth $1,949,000. Finally, Public Employees Retirement System of Ohio purchased a new stake in Atrion in the 1st quarter worth about $2,299,000. 66.19% of the stock is owned by institutional investors.

About Atrion

Atrion Corporation, together with its subsidiaries, develops, manufactures, and sells products for fluid delivery, cardiovascular, and ophthalmic applications in the United States, Canada, Europe, and internationally. The company's fluid delivery products include valves that fill, hold, and release controlled amounts of fluids or gasses for use in various intubation, intravenous, catheter, and other applications in the anesthesia and oncology fields, as well as promote infection control in hospital and home healthcare environments.